Mesna: adverse event reports filed with FDA

4,393

reports as suspect product

0% of all reports · about 195 a year

325

reports, 12 months to June 2026

403 in the 12 months before

98.3%

marked serious by the reporter

98.2% across the class

20.1%

record death among outcomes, as reported

885 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Mesna reports recording the termmedian drug in cytoprotective agent

1. Febrile neutropeniafever with low white blood cells18.1%794
2. Pyrexiafever8.2%360
3. Off label useused for a purpose or in a way not on the label7.4%326
4. Neutropenialow neutrophils, a type of white blood cell6.3%277
5. Vomitingbeing sick5.3%234
6. Sepsisa severe body-wide response to infection4.7%207
7. Pancytopenialow counts of all blood cells4.4%195
8. Disease progressionthe disease advanced4.3%189
9. Diarrhoealoose or frequent stools4.2%183
10. Thrombocytopenialow platelets4.1%182
11. Anaemialow red blood cells4.1%178
12. Nauseafeeling sick4%176
13. Deaththe patient died; cause not stated by this term3.4%149
14. Pneumonialung infection3.3%145
15. Encephalopathy3.3%144
16. Hypotensionlow blood pressure3.2%139
17. Mucosal inflammation3.2%139
18. Bacterial infectiona bacterial infection3.1%138
19. Myelosuppression2.7%118
20. Drug ineffectivethe medicine did not work as expected2.7%117
21. Platelet count decreasedlow platelet count2.6%115
22. Product use in unapproved indicationused for a purpose not on the label2.5%112
23. Viral infectiona viral infection2.5%111
24. White blood cell count decreasedlow white cell count2.5%108
25. Infectionan infection, type not specified2.4%107
26. Pseudomonal sepsis2.4%107
27. Bronchopulmonary aspergillosis2.4%104
28. Cytokine release syndrome2.3%101
29. Neutrophil count decreased2.1%92
30. Acute kidney injurysudden loss of kidney function2.1%91

Top 30 of 843 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 3 drugs in the cytoprotective agent class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 13,325 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 34.3% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 4,393 reports.

Drugs most often listed in the same reports

Other products listed in reports where Mesna is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the cytoprotective agent class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Mesna as a suspect or interacting product; reports listing it only as a concomitant medication (3,904) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.